These results physiologically reconfirmed the lower differential ability of Lexa (compared with other DR5 agonists) to engage DR5 on human tumor cells despite activating effective cell death (Figure 1B versus 1E). The gene discussed is TNFRSF10B; the disease is neoplasm.